The Board of Directors of EXACT Therapeutics AS wishes to accommodate the
liquidity of the shares of EXACT Therapeutics and the Board has decided to
propose a share split as further described below. The proposal will be presented
for approval at the EGM on 24 July 2020. 

Date on which the corporate action is made public: 16 July 2020
Split ratio: 1 old share will give 250 new shares
Last day inclusive right to have 1 share traded into 250 shares: 24 July 2020
(being the date of the EGM)
Ex-date: 27 July 
Record date: 28 July 2020 
Date of approval: 24 July 2020

For further queries, please contact: 
Masha Stromme, Chair +47 93022509
Stig Jarle Pettersen, CFO +47 90960336

EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated,
targeted drug enhancement - with the potential to significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy), infectious
diseases, and neurological conditions. www.exact-tx.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange